In clinical practice, there is a frequent need to switch between P2Y12 receptor inhibitors. However, concerns on drug interactions have emerged when switching therapies. To date, the PD effects of switching from ticagrelor to clopidogrel have yet to be investigated.

This prospective study was carried out in the department of cardiology, during a period from November 2015 to October 2018. A total of 683consecutive patients with acute coronary syndromes without ST segment elevation (UA/NSTEMI) undergoing percutaneous coronary intervention were included in the study. We examined GUSTO moderate or severe bleeding, major adverse cardiovascular events (MACEs), and definite stent thrombosis events around the time of the switch and after a one year follow up. The patients take ticagrelor for 30days from PCI and switch to clopidogrel in day 30taking ticagrelor and clopidogrel in this same day.

Switching occurred at a median of 30days postdischarge. Comparing the 7days preceding and following the switch to clopidogrel, we don’t not any upsurge of MACE or modification of GUSTO moderate or severe bleeding event and any stent thrombosis.

Postdischarge ADPri switching can occure frequently from ticagrelor to clopidogrel within the first days post-PCI and was not associated with significant MACEs or bleeding events after switching at one month in our study.